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Abstract
Killer immunoglobulin-like receptors (KIRs) regulate the activation of 
natural killer cells through their interaction with human leucocyte an-
tigens (HLA). KIR and HLA loci are highly polymorphic, and certain 
KIR/HLA combinations have been found to protect against viral in-
fections or to predispose to autoimmune disorders. In particular, some 
activating KIR proﬁles may be detrimental in autoimmune pathogene-
sis, and speciﬁc KIR genes may be particularly aggressive in the clearan-
ce of different microorganisms, protecting individuals in the control of a 
given pathogen. Here we reviewed a growing body of evidence purpor-
ting the influence of KIR polymorphism and KIR-HLA interaction in the 
development of the main human autoimmune and viral diseases.
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State of the art
Killer immunoglobulin-like receptors (KIRs) are surface receptors 
speciﬁc for allelic forms of human leukocyte antigen (HLA) class I 
molecules, which are expressed by natural killer (NK) cells and a sub-
set of CD8 T lymphocytes. The polygenic nature of the KIR locus is 
particularly consequential in a functional sense because KIR genes 
encode receptors that can either inhibit or activate both cell types 
[Campbell & Purdy, 2011]. 
The KIR gene cluster consists of a segment of about 150 kb situated 
on chromosome 19q13.4 within the leukocyte receptor complex. To date, 
15 KIR genes and 2 pseudogenes have been described. However, varia-
bility in gene content at the KIR locus appears largely due to gene dupli-
cation and non-allelic homologous recombination [Martin et al., 2003]. 
KIR genes are organized in two basic haplotypes that have been de-
ﬁned on the basis of gene content, and are termed A and B. Haplotype 
A is uniform in terms of gene content and is composed of ﬁve inhibi-
tory genes (KIR2DL1, 2DL3, 3DL1, 3DL2 and 3DL3), one activating 
gene (KIR2DS4), and KIR2DL4, which may have both inhibitory and 
activating capacity. Interestingly, many A haplotypes possess null va-
riants of both KIR2DS4 and KIR2DL4 that are not expressed on the 
cell surface [Hsu et al., 2002; Witt et al., 2000]. Accordingly with this, 
these haplotypes do not have functional activating KIR. 
The B haplotypes contain variable numbers of activating and inhi-
bitory receptors and are the primary contributors to the extraordinary 
differences in gene proﬁles observed in distinct ethnic populations. Al-
though at different frequency, A and B haplotypes have been maintained 
within the human population, suggesting the occurrence of a balancing 
selection. A haplotypes seem to be associated with improved responses 
to pathogens, whereas B haplotypes with improved reproductive ﬁtness 
[Moffett & Loke, 2006; Parham, 2005; Rajagopalan & Long, 2005]. 
Much of the variability among KIR haplotypes derives from the pre-
sence or the absence of activating KIR, because most of the inhibitory KIRs 
are present on all or nearly all haplotypes [Uhrberg et al., 1997]. The inhi-
bitory KIR family is characterized by cytoplasmic immunoreceptor tyro-
sine-based inhibition motifs (ITIMs), which recruit the SHP-1/2 tyrosine 
phosphatases preventing NK cells activation. On the contrary, the acti-
vating KIRs have short cytoplasmic tails lacking ITIMs (i.e., KIR2DS and 
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KIR3DS), which interact with DAP12; this is an adaptor molecule that con-
tains immunoreceptor tyrosine-based activation motifs (ITAMs) linked to 
protein tyrosine kinase activation pathways [Parham & Moffett, 2013]. 
The activating KIRs stimulate NK/CD8 T lymphocytes cytokine secretion 
and target cell cytolysis may be generally beneﬁcial in response to micro-
organisms and tumor cells. Not all inhibitory or activating receptors are 
present on the surface of NK or CD8 T cells and it is the balance of these 
signals that modulates NK cells cytotoxicity and cytokine release.
Most inhibitory KIRs speciﬁcally recognize sets of HLA class I 
(i.e., HLA-A, -B, and -C) allotypes; yet, the ligands for some of them 
(e.g., KIR2DL5) and for most activating KIRs are unknown. 
HLA class I genes map to chromosome 6. These genes are extre-
mely polymorphic, determining functional diversity, and generating 
variable susceptibility in response to pathogens and other diseases. 
The inhibitory KIR2DL1, 2DL2, and 2DL3 recognize HLA-C li-
gands, that belong to one of two ligand groups based with a dimor-
phism at position 80: group 1 (HLA-C1), which has asparagine, and 
group 2 (HLA-C2), which has lysine at position 80 [Winter & Long, 
1997]. KIR3DL1 is known to bind HLA-B allotypes with the Bw4 motif, 
although some low affinity binding with Bw6 has also been reported 
[Carr et al., 2005; Cella et al., 1994; Gumperz et al., 1995]. Other re-
ceptor–ligand relationships among KIRs and HLA include KIR2DL4 
speciﬁcity for HLA-G, which is primarily expressed on foetal tropho-
blasts, thymic endothelial cells and cornea, and KIR3DL2 speciﬁcity 
for HLA-A3 and A11 [Dohring et al., 1996; Rajagopalan & Long, 1999]. 
The activating receptors KIR2DS1, 2DS2 and 3DS1 share sequen-
ce similarity in their extracellular domains with their corresponding 
inhibitory counterparts (KIR2DL1, 2DL2-2DL3 and 3DL1, respecti-
vely) and are thought to share HLA ligand binding speciﬁcities as 
well [Kulkarni et al., 2008]. 
Combinations of HLA and KIR genes have been associated with se-
veral diseases such as infectious diseases, autoimmune/inflammatory 
disorders, cancer and reproduction. Emerging functional data supports a 
mechanism based on a continuum of inhibition to activation through va-
rious compound KIR/HLA genotypes in diseases [Kulkarni et al., 2008]. 
Moreover, allelic variation also plays a role in determining the strength 
of the interaction [Yawata et al., 2006]. The diversity of KIR haplotypes, 
which likely imparts a continuum from relatively strong inhibition to 
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strong activation, suggests the pleiotropic nature of KIR on different 
diseases in that a given KIR genotype affording protection against one 
disease may actually predispose to another unrelated disorder.
In this regard, activating KIR proﬁles might be detrimental in au-
toimmune pathogenesis, potentially aggravating the disease process, 
although, this may be true for only certain autoimmune diseases and 
quite the opposite for others [Baxter & Smyth, 2002; Flodstromet et 
al., 2002a]. KIR associations with susceptibility to autoimmune condi-
tions point to the short chain of the activating KIR. Moreover, the NK 
cell control of viral infections has been the subject of excellent reviews 
[Brandstadter & Yang, 2011]. Speciﬁc KIR genes may be particularly 
aggressive in the clearance of some microorganisms, and their pre-
sence in only a fraction of individuals (as well as their allelic poly-
morphism) could explain differences observed among individuals in 
their ability to control a given pathogen.
KIR/HLA association and autoimmune diseases
Currently about 5% of the population of the developed countries 
is affected by various types of autoimmune diseases [Flodstrom et 
al., 2002b]. The background of autoimmune diseases is multifactorial 
and remains unclear. However, the robust associations between the 
highly polymorphic HLA class I/class II loci and autoimmune disea-
ses are strong [Matzaraki et al., 2017]. It would not be surprising if the 
strongest effects of KIR variation were also observed in autoimmune 
diseases. Some previously determined HLA associations with au-
toimmune diseases might actually be explained by synergistic inte-
ractions between KIR and alleles encoding their HLA class I ligands. 
On the other hand, NK cell activation may be protective against some 
autoimmune disorders by suppressing or eliminating dendritic cells 
and monocytes [Geldhof et al., 1998], cells known to stimulate the 
generation of cytotoxic T lymphocytes (see Table 1 for an overview). 
A number of studies have investigated KIR expression in rheuma-
toid arthritis (RA). RA was the ﬁrst disease in which an effect of KIR 
genotype was observed. In RA patients, where CD4+ CD28null T cells are 
expanded and cause endothelial damage, it was showed that these cells 
expressed KIR2DS2 in the absence of inhibitory KIR2DL2 [Namekawa 
et al., 2000]. Further, the frequency of KIR2DS2 was increased in RA 
patients with vasculitis in comparison to normal controls and RA pa-
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tients without vasculitis [Yen et al., 2001]. HLA-Cw*03, an HLA-C1 al-
lotype, and therefore a putative ligand for KIR2DS2, was also increased 
in subjects with vasculitis, although this was not true for other C1 alleles 
[Yen et al., 2001]. Thus, it is possible that KIR2DS2 recognizes a speciﬁc 
HLA-Cw*03-peptide complex generated during RA vasculitis. 
Activating B haplotypes of KIR [Suzuki et al., 2004] and KIR2DS1 
alone [Luszczek et al., 2004] or in combination with HLA-Cw6 (a C2 
ligand for KIR2DS1) have been reported to associate with psoria-
sis [Holm et al., 2005]. Based on the data, a model was proposed in 
which a gradient of more activating to more inhibitory compound 
genotypes of KIR2DS and HLA-C appear to influence susceptibili-
ty to psoriatic arthritis. So, genotypes conferring highest activation 
(KIR2DS1 and/or KIR2DS2 with either HLA-C1 or C2 homozygosi-
ty) are associated with greatest susceptibility, whereas the genotypes 
conferring maximum inhibition (absence of activating receptors 
KIR2DS1 and KIR2DS2 and presence of both the inhibitory ligands, 
such as HLA-C1 and C2) were protective.
Moreover, the association between KIR gene polymorphisms and 
systemic lupus erythematosus (SLE) risk has been investigated by 
many case-control studies, but ﬁndings are not always consistent. 
SLE is a multifactorial and highly polymorphic systemic autoimmu-
ne disease that predominantly afflicts women in child-bearing age. It 
is a complex interaction result of genetic, environmental., and hormo-
nal factors, companying a global loss of immune tolerance [Maselli 
et al., 2016]. In 2007, Pellett et al., ﬁrst reported that the frequency of 
KIR2DS1 was signiﬁcantly increased in SLE patients compared with 
controls [Pellett et al., 2007]. In addition, a recent meta-analysis shows 
that KIR2DL1 might be a potential risk factor for SLE in Caucasians 
and KIR2DL3, KIR2DL5 might be protective factors for SLE in Asians 
[Liang et al., 2017], indicating that the association between KIR poly-
morphisms and the risk of SLE may be different in different ethnic 
populations. In addition, activating KIR proﬁles, like KIR2DS2/
KIR2DS5/KIR2DS1 were signiﬁcantly higher in SLE patients as com-
pared to healthy persons; however, it was seen that various ethnic 
and environmental factors might influence susceptibility to disease, 
which is consistent with previous studies [Pedroza et al., 2016].
An increasing stream of studies has been designed with systemic scle-
rosis (SSc) and ankylosing spondylitis (AS) patients to investigate the re-
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lation between autoimmunity and KIR. SSc is a chronic disease of the con-
nective tissue characterized by the ﬁbrosis of the skin associated with the 
structural and functional damages of various organs such as the gastroin-
testinal system, lungs, heart, kidneys. It is a global disease and affects all 
races, and women are more susceptible than men [Romano et al., 2011]. It 
was seen that KIR2DS2 was more frequently highlighted in these studies. 
In fact, it was reported as a risk factor in the absence of KIR2DL2 in SSc 
patients. Moreover, the KIR2DS3 gene was more frequent in SSc patients 
than in controls, instead the KIR2DL3 gene was detected more frequently 
in controls while KIR2DS3 gene was more frequent in the patient group 
when SLE and SSc were combined [Tozkir et al., 2016].
In AS strong epidemiological evidence of signiﬁcant genetic asso-
ciations with HLA has been convincingly identiﬁed. AS is a chronic 
inflammatory disease which primarily affects the sacroiliac joint and is 
characterized by strong genetic association with HLA-B27 [Mathieu et 
al., 2008]. HLA-B27 interactions with KIR have been implicated in the 
pathogenesis of AS, with consistent differences among populations. 
KIR3DL1, for example, and possibly KIR3DS1, interact with classical 
B27, whereas KIR3DL2 binds B27 heavy chain dimers [Cauli et al., 
2014]. Moreover, it was suggested that reduced HLA-Bw4 genotype 
with and without its inhibitory receptor KIR3DL1, may influence the 
inhibitory effect of NK cytotoxicity leading to continued injury in AS. 
Further work in this area will help to establish the role of KIR/
HLA association in autoimmune disease development.
Table 1. KIR-HLA associations in autoimmune diseases. 
Disease KIR–HLA ligand pair Effect
Rheumatoid 
arthritis
KIR2DS2/HLA-Cw*03 Susceptibility
Psoriasis KIR2DS1/HLA-Cw*06 
KIR2DS1; KIR2DL5; KIR haplotype B
Susceptibility
Susceptibility
Systemic lupus 
erythematosus
KIR2DS2; KIR2DS5; KIR2DS1 Susceptibility
Systemic 
sclerosis
KIR2DS2 in the absence of KIR2DL2 
KIR2DS3
Susceptibility
Susceptibility
Ankylosing 
spondylitis
KIR3DL1/ HLA-B27 Susceptibility
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KIR/HLA association and viral diseases
Several epidemiological studies have associated KIR/HLA geno-
types with susceptibility to some infectious diseases such as human 
immunodeﬁciency virus (HIV), human cytomegalovirus (CMV), and 
hepatitis C virus (HCV) [Cook et al., 2006; Di Bona et al., 2014; Kha-
koo et al., 2004; Hadaya et al., 2008; Martin et al., 2002; Martin et al., 
2007; Stern et al., 2008]. So far, there are limited data on the relation-
ship between KIR genes and their HLA ligands and the outcome of 
hepatitis B virus (HBV) infection (see Table 2 for an overview).
HIV prevalence is increasing worldwide because people on an-
tiretroviral therapy are living longer, although new infections de-
creased from 3.3 million in 2002, to 2.3 million in 2012. New insights 
into the mechanisms of latent infection and the importance of reser-
voirs of infection might eventually lead to a cure. The role of immune 
activation in the pathogenesis of non-AIDS clinical events (major 
causes of morbidity and mortality in people on antiretroviral thera-
py) is receiving increased recognition [Sharp & Hahn, 2011]. In indi-
viduals infected with HIV, the combination of KIR3DS1 with its pu-
tative ligand HLA-Bw4-80I was associated with slower progression 
to AIDS, lower mean viral load, and protection against opportunistic 
infections [Martin et al., 2007; Qi et al., 2006]. Moreover, a study of 25 
HIV exposed uninfected intravenous drug users from Vietnam found 
transcription of KIR3DS1 to be signiﬁcantly higher than KIR3DL1 in 
KIR3DS1/3DL1 heterozygous individuals and there was expansion 
of NK cells expressing KIR2DL3 in HLA-C1/C1 individuals who 
were KIR2DS2−/2DL2− [Ravet et al., 2007]. KIR3DS1 homozygosity 
was also found to be signiﬁcantly increased in HIV exposed seroneg-
ative intravenous drug users and HIV negative partners of sero-dis-
cordant couples [Boulet et al., 2008]. These individuals also had an 
increase in KIR AB haplotypes, which are characterized by increased 
numbers of activating KIR.
Also the variability in the association of host innate immune re-
sponse to HCV infection requires the possible role of host KIR and 
HLA genotypes in HCV-related disorders. The World Health Orga-
nization estimates that about 3% of the world population is infected 
with HCV, and 3 to 4 million individuals are newly infected each 
year. Although new antiviral treatments are very promising, today 
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only a minority of patients successfully clear up HCV infections, 
and the remaining patients (60–85%) develop chronic infection [Af-
dhal et al., 2014]. NK cells have also been reported to play a role in 
HCV clearance [Cheent & Khakoo, 2011]. In particular, NK cells were 
demonstrated to mediate the inhibition of HCV-replication and to 
exert a targeted cytotoxic action against targeted cells given that NK 
cells isolated from healthy donors kill HCV-replicating cells and se-
crete IFN-γ [Larkin et al., 2006; Stegmann et al., 2010]. 
HLA-C1/KIR2DL3 in homozygosis has been associated with HCV 
clearance in several studies but the occurrence of this association was 
not always observed. At the same time, HLA-C1/KIR2DL3 has also 
been associated with sustained virus response to anti-HCV therapy.
Moreover, a protective role for HLA-Bw4/KIR3DS1 against liver dis-
ease progression has been proposed [De Re et al., 2015]. Previous data 
have also suggested that KIR2DL1/HLA-C2 may confer stronger inhibi-
tory responses than does KIR2DL3/HLA-C1 [Ahlenstiel et al., 2008].
CMV is a member of the herpes virus family (type 5) that is ubiq-
uitous in human populations, reaching a prevalence of 100% in Africa 
and Asia, and approximately 80% in Europe and the United States, de-
pending on socioeconomic status. Clinically, primary CMV infection is 
assumed to be asymptomatic in the immunocompetent host, but a mi-
nority of subjects (<10%) exhibit symptoms of the infection, such as mal-
aise, fever, sweating, and abnormal liver function [Cannon et al., 2010]. 
There is increasingly compelling evidence that NK cells play a crucial 
role in host defence against CMV infection. In order to evade the im-
mune system, CMV encode several proteins that interfere with MHC 
class I expression, potentially rendering infected cells more susceptible 
to attack by NK cells [Lin et al., 2007]. In a case study of a child with 
a novel immunodeﬁciency syndrome and recurrent CMV infection, the 
entire population of NK cells from this patient expressed KIR2DL1 and 
the child also possessed the KIR2DL1 ligand, HLA-C2, raising the possi-
bility that the strongly inhibitory KIR2DL1/HLA-C2 combination crip-
pled NK cell activity and prevented the cells from mounting a protec-
tive response against CMV [Gazit et al., 2004]. Recent reports have also 
documented a role for activating KIRs in the control of CMV infection 
after hematopoietic stem cell or kidney transplantation, showing that the 
CMV reactivation rate in patients homozygous for the KIR A haplotype 
(virtually without activating KIRs) is higher than in patients with the B 
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haplotype (with a variable number of activating KIRs), suggesting the 
importance of activating KIRs in the immune surveillance against CMV 
[Cook et al., 2006; Hadaya et al., 2008; Stern et al., 2008]. Moreover, it 
was showed that immunocompetent subjects carrying the homozygous 
A haplotype or the HLA-Bw4T allele are at higher risk of developing 
symptomatic disease after primary CMV infection. The frequency of the 
homozygous A haplotype (only KIR2DS4 as activating KIR) was higher 
in symptomatic patients than controls. By logistic regression, the risk of 
developing symptomatic disease was associated with the homozygous 
A haplotype and the HLABw4T allele [Di Bona et al., 2014]. 
HBV is a hepatotrophic virus that causes a major global health 
problem. An estimated 2 billion individuals have been infected with 
HBV and approximately 350 million have the chronic disease. NK 
cells are activated in the early response to infection, and there is sub-
stantial population variability in the rates of HBV infection [Custer B 
et al., 2004]. Although detailed genetic and functional analyses explo-
ring KIR influences on HBV in large cohorts are lacking, accumula-
ting evidence supports that NK cell activation contributes to inflam-
mation and liver injury during HBV infection both in HBV transgenic 
mice and in HBV infected patients [Chen et al., 2007; Dunn et al., 2007; 
Kakimi et al., 2001]. However, in a Turkish cohort, the rate of inhibi-
tory KIR2DL3 and 3DS1 were higher in the healthy group than in the 
group composed of chronic HBV patients and patients with spon-
taneous remission. There were no statistically signiﬁcant differences 
between the rate of AA and Bx genotypes of chronic HBV patients and 
patients with spontaneous remission and the control group. Moreo-
ver, a case-control study showed that more copies of HLA-C1 alleles, 
which resulted in inherently more potent NK cells, were associated 
with disease progression towards hepatocellular carcinoma (HCC) 
(one copy associated with cirrhosis; two copies associated with HCC) 
in HBV-infected patients, suggesting that NK cell activation may play 
a role in HCC development [Pan et al., 2011]. Finally, in a recent study, 
the authors compared the frequencies of KIR and HLA gene families 
in subjects with chronic hepatitis B (CHB) and subjects with resolved 
infection [Di Bona et al., 2017]. The inhibitory KIR2DL3 gene was less 
frequent in CHB (81%) than in subjects with resolved infection (98%). 
The only other KIR gene expressed differently between CHB and 
subject with resolved infection was the KIR2DS4-Del, which codes 
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for an inactive receptor. No difference was reported in the frequency 
of KIR haplotypes between the groups, suggesting that activating re-
ceptors likely do not play a role in the control of the infection. These 
results suggest that a combination of KIR/HLA gene/alleles is able 
to predict the outcome of HBV infection. 
These data suggest that speciﬁc KIR and HLA gene segregations 
were likely the result of a pathogen selective pressure.
Table 2. KIR-HLA associations in viral infections.
Disease KIR–HLA ligand pair Effect
HIV KIR3DS1/HLA-Bw4-80I 
KIR3DL1*004/HLA-Bw4 
KIR3DS1 
Slower progression Slow-
er progression 
Reduced risk of infection 
CMV KIR2DL1 expression on all NK cells 
>1 activating KIR in donor in 
bone marrow transplantation
KIR A haplotype/HLA-Bw4T 
Recurrent CMV infection 
Protection from CMV re-
activation in
the recipient
Higher risk of developing 
symptomatic disease
HCV KIR2DL3/HLA-C1 homozygosity Resolution of infection
HBV KIR2DL3; KIR3DS1
KIR2DL3/HLA-A-Bw4 and 
HLA-C2
Lower in chronic HBV 
patients
Development of chronic 
hepatitis B 
Discussion
Combinations of HLA class I and KIR variants have been associa-
ted with pathologies as autoimmunity, viral infections, pregnancy-re-
lated disorders and cancer [Parham, 2005; Khakoo & Carrington, 
2006]. Thus, interactions between KIR and HLA class I polymorphi-
sms have probably been involved in human during incidences of 
epidemic infections and have affected reproduction and population 
expansion. These types of selection pressures might explain the fun-
ctional coevolution of KIR with diverging HLA class I molecules and 
why KIR sequences, like the HLA loci, are highly polymorphic and 
rapidly evolving [Guethlein et al., 2007; Martin et al., 2007].
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Multiple factors complicate the interpretation of KIR-HLA disease 
association, including the extensive polymorphism of the KIR and HLA 
class I ligands, the incomplete knowledge of KIR ligands, the oversim-
pliﬁcation of the structural complexities of their interactions, and limited 
understanding of KIR gene expression control [Traherne, 2008].
In general., KIR-HLA combinations with a tendency towards 
stronger NK cell activation or lower levels of inhibition are associated 
with increased risk of autoimmune diseases but tend to be protective 
against infectious diseases. 
The reviewed data are consistent with the idea that disease suscep-
tibility is modiﬁed by speciﬁc KIR-HLA ligand interactions. For this 
reason several studies have examined KIR and HLA class I combina-
tions in disease association studies. Such studies will need to be large, 
with well-controlled populations, in order to be adequately powered. 
Conclusion
In NK cell education, KIR/HLA interactions are required to 
establish self-tolerance and to shape the KIR repertoire of fully fun-
ctional NK cells. It is clear that the association of activating KIR ge-
notypes increases risk of autoimmune diseases and decreased risk 
of some infectious disease outcomes. Further efforts and incremental 
experiments are necessary to deﬁne the role of KIR-HLA interaction 
in human disease, and in turn, to potentially apply this knowledge 
clinically, and to deﬁne a common threads of KIR involvement across 
diseases that share some etiological characteristics.
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